mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease
Identifieur interne : 000168 ( Pmc/Curation ); précédent : 000167; suivant : 000169mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease
Auteurs : Corey. Hopkins [États-Unis] ; Craig. Lindsley [États-Unis] ; Colleen. Niswender [États-Unis]Source :
- Future medicinal chemistry [ 1756-8919 ] ; 2009.
Abstract
Although Parkinson’s disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-l-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinson’s disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson’s disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinson’s disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinson’s disease.
Url:
DOI: 10.4155/fmc.09.38
PubMed: 20161443
PubMed Central: 2790174
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000168
Links to Exploration step
PMC:2790174Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease</title>
<author><name sortKey="Hopkins, Corey R" sort="Hopkins, Corey R" uniqKey="Hopkins C" first="Corey" last="Hopkins">Corey. Hopkins</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lindsley, Craig W" sort="Lindsley, Craig W" uniqKey="Lindsley C" first="Craig" last="Lindsley">Craig. Lindsley</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Niswender, Colleen M" sort="Niswender, Colleen M" uniqKey="Niswender C" first="Colleen" last="Niswender">Colleen. Niswender</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20161443</idno>
<idno type="pmc">2790174</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790174</idno>
<idno type="RBID">PMC:2790174</idno>
<idno type="doi">10.4155/fmc.09.38</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">000168</idno>
<idno type="wicri:Area/Pmc/Curation">000168</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease</title>
<author><name sortKey="Hopkins, Corey R" sort="Hopkins, Corey R" uniqKey="Hopkins C" first="Corey" last="Hopkins">Corey. Hopkins</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lindsley, Craig W" sort="Lindsley, Craig W" uniqKey="Lindsley C" first="Craig" last="Lindsley">Craig. Lindsley</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="A2">Department of Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Niswender, Colleen M" sort="Niswender, Colleen M" uniqKey="Niswender C" first="Colleen" last="Niswender">Colleen. Niswender</name>
<affiliation wicri:level="1"><nlm:aff id="A1">Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Future medicinal chemistry</title>
<idno type="ISSN">1756-8919</idno>
<idno type="e-ISSN">1756-8927</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Although Parkinson’s disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-l-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinson’s disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson’s disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinson’s disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinson’s disease.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101511162</journal-id>
<journal-id journal-id-type="pubmed-jr-id">36717</journal-id>
<journal-id journal-id-type="nlm-ta">Future Med Chem</journal-id>
<journal-title>Future medicinal chemistry</journal-title>
<issn pub-type="ppub">1756-8919</issn>
<issn pub-type="epub">1756-8927</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">20161443</article-id>
<article-id pub-id-type="pmc">2790174</article-id>
<article-id pub-id-type="doi">10.4155/fmc.09.38</article-id>
<article-id pub-id-type="manuscript">NIHMS133120</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Hopkins</surname>
<given-names>Corey R</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lindsley</surname>
<given-names>Craig W</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Niswender</surname>
<given-names>Colleen M</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Department of Pharmacology, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</aff>
<aff id="A2"><label>2</label>
Department of Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-36000, USA</aff>
<author-notes><corresp id="CR1"><label>†</label>
Author for correspondence Tel.: +1 615 936 6892 Fax: +1 615 343 9332 <email>corey.r.hopkins@vanderbilt.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>5</day>
<month>11</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="ppub"><day>1</day>
<month>6</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>4</month>
<year>2010</year>
</pub-date>
<volume>1</volume>
<issue>3</issue>
<fpage>501</fpage>
<lpage>513</lpage>
<permissions><copyright-statement>© 2009 Future Science Ltd</copyright-statement>
<copyright-year>2009</copyright-year>
</permissions>
<abstract><p id="P1">Although Parkinson’s disease was first diagnosed nearly 200 years ago, its effective treatment still remains elusive for most of those diagnosed. The gold standard of treatment for most patients is 3,4-dihydroxy-l-phenylalanine. This drug works for most individuals early in the disease; however, resistant symptoms start to emerge after several years of treatment. There has been increased interest in finding novel therapies to help Parkinson’s disease patients. Such strategies may have the benefit of not only treating the symptomatic issues of the disorder, but might also offer promise in protecting dopaminergic neurons from further degeneration. One such target that is now receiving much attention from the scientific community is the metabotropic glutamate receptor mGluR4. In this article, we briefly review Parkinson’s disease and then recent work in the mGluR area, with a focus on the efforts being made toward finding and optimizing novel mGluR4 positive allosteric modulators (PAMs). Preclinically in rodent models, mGluR4 activation has offered much promise as a novel treatment of Parkinson’s disease. Additionally, the specific use of PAMs, rather than direct-acting agonists at the orthosteric glutamate site, continues to be validated as a viable treatment option for this target. It is anticipated that continued progress in this area will further our understanding of the potential of mGluR4 modulation as a novel symptomatic and potentially disease-modifying treatment for Parkinson’s disease.</p>
</abstract>
<contract-num rid="NS1">R01 NS048334-05
||NS</contract-num>
<contract-sponsor id="NS1">National Institute of Neurological Disorders and Stroke : NINDS</contract-sponsor>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000168 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000168 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= JankovicV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:2790174 |texte= mGluR4-positive allosteric modulation as potential treatment for Parkinson’s disease }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:20161443" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a JankovicV1
![]() | This area was generated with Dilib version V0.6.19. | ![]() |